Sample size/power for PD BE study 3-way crossover [Power / Sample Size]

posted by Dr_Dan  – Germany, 2011-03-30 12:13 (5571 d 20:34 ago) – Posting: # 6832
Views: 10,508

Dear Coja66
In order to understand your problem additional information is needed. First HVD: regarding PK or PD? Highly intra-subject variability regarding pharmacokinetic parameters do not necessary mean highly intra-subject variability regarding pharmacodynamic outcome although in general pharmacodynamic parameters are more variable than kinetic. What is the range of the PD parameter?
Second: Your study, is it a proof-of-concept study or a pivotal BE study? I personally would not recommend to test two test formulations in a pivotal study. In case of highly variable drugs I recommend to use a full replicate design. In general a 6x3 way design is not possible due to blood loss, but in your case it is different. Increasing the numbers of periods also means to increase the probability of drop outs.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
274 visitors (0 registered, 274 guests [including 15 identified bots]).
Forum time: 08:47 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5